What Wegovy Is: The Complete Medical Definition, Mechanism, and Clinical Context You Won't Find Elsewhere

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy is the brand name for semaglutide 2.4 mg, a once-weekly injectable GLP-1 receptor agonist FDA-approved specifically for chronic weight management in adults with obesity or overweight plus weight-related conditions
• The molecule is identical to Ozempic's active ingredient but dosed higher (2.4 mg vs 1 mg max) and carries a different FDA indication (obesity vs type 2 diabetes)
• Semaglutide mimics human GLP-1 hormone with a 94% amino acid sequence match, modified with a fatty acid side chain that extends half-life from 2 minutes to 7 days
• Wegovy became the first GLP-1 medication FDA-approved for obesity in June 2021, based on the STEP trial program showing 15% average total body weight loss over 68 weeks

Direct answer (40-60 words)

Wegovy is Novo Nordisk's brand name for semaglutide 2.4 mg, a synthetic GLP-1 receptor agonist approved by the FDA for chronic weight management. It's a once-weekly subcutaneous injection that slows gastric emptying, reduces appetite, and improves glucose regulation. The active molecule is chemically identical to Ozempic but prescribed at higher doses specifically for obesity treatment.

Table of contents

1. The molecular definition: what semaglutide actually is
2. How Wegovy differs from Ozempic, Rybelsus, and compounded semaglutide
3. The mechanism: three pathways that cause weight loss
4. The FDA approval context: why Wegovy exists as a separate product
5. The STEP trials: the evidence base behind the 2.4 mg dose
6. What most articles get wrong about "Wegovy vs Ozempic"
7. The FormBlends clinical pattern: who gets prescribed what
8. Wegovy's place in the 2026 obesity treatment algorithm
9. The supply and cost reality: why compounded semaglutide emerged
10. When Wegovy is the right choice vs when it's not
11. The future: what happens when the shortage ends
12. FAQ

The molecular definition: what semaglutide actually is

Wegovy's active pharmaceutical ingredient is semaglutide, a synthetic analog of human glucagon-like peptide-1 (GLP-1). The molecule is a 31-amino-acid peptide with 94% sequence homology to native human GLP-1.

The critical modification is at position 8, where an alanine is replaced with aminoisobutyric acid (AIB), and position 26, where a lysine is attached to a C18 fatty diacid chain via a small spacer. This fatty acid side chain allows semaglutide to bind reversibly to albumin in the bloodstream, which protects it from rapid degradation by dipeptidyl peptidase-4 (DPP-4), the enzyme that normally breaks down GLP-1 within 2 minutes of secretion.

The result: semaglutide's half-life is approximately 7 days, compared to 2 minutes for endogenous GLP-1. This extended half-life enables once-weekly dosing instead of multiple daily injections.

The chemical formula is C₁₈₇H₂₉₁N₄₅O₅₉, with a molecular weight of 4,113.58 Da. It's manufactured using recombinant DNA technology in yeast cells (Saccharomyces cerevisiae), then purified and formulated with disodium phosphate dihydrate, propylene glycol, phenol, and water for injection.

Semaglutide was first synthesized by Novo Nordisk researchers in 2012 as part of a program to develop longer-acting GLP-1 agonists. The molecule received FDA approval as Ozempic (for type 2 diabetes) in December 2017 and as Wegovy (for obesity) in June 2021.

How Wegovy differs from Ozempic, Rybelsus, and compounded semaglutide

All four products contain semaglutide as the active ingredient. The differences are formulation, dose, and FDA indication.

Product	Active ingredient	Formulation	Max dose	FDA indication	Approval date
Wegovy	Semaglutide	Subcutaneous injection	2.4 mg weekly	Chronic weight management (obesity)	June 2021
Ozempic	Semaglutide	Subcutaneous injection	2 mg weekly*	Type 2 diabetes	December 2017
Rybelsus	Semaglutide	Oral tablet	14 mg daily	Type 2 diabetes	September 2019
Compounded semaglutide	Semaglutide	Subcutaneous injection (typically)	Varies (often mirrors Wegovy dosing)	None (compounded drugs are not FDA-approved)	N/A

*Ozempic's labeled max dose is 2 mg weekly, though the 2.4 mg dose exists in the same pen device and is sometimes prescribed off-label for weight loss.

The molecule in Wegovy and Ozempic injections is identical. The difference is regulatory: Wegovy underwent separate Phase 3 trials (STEP 1-5) at the 2.4 mg dose specifically for obesity, while Ozempic's trials (SUSTAIN 1-10) tested doses up to 1 mg (later 2 mg) for diabetes.

Rybelsus uses the same semaglutide molecule but adds the absorption enhancer SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) to enable oral absorption. Oral bioavailability is roughly 1%, so a 14 mg oral dose delivers approximately the same systemic exposure as 1 mg injected.

Compounded semaglutide is prepared by state-licensed compounding pharmacies using bulk semaglutide powder (typically sourced from FDA-registered facilities or imported under specific allowances). It's formulated to mirror Wegovy or Ozempic dosing but has not undergone FDA review for safety, efficacy, or manufacturing consistency. Compounded versions are legal under Section 503A of the Federal Food, Drug, and Cosmetic Act when the brand-name drug is in shortage, which semaglutide has been since early 2022.

The mechanism: three pathways that cause weight loss

Semaglutide causes weight loss through three distinct physiological mechanisms, all mediated by GLP-1 receptor activation.

1. Central appetite suppression.

GLP-1 receptors are densely expressed in the hypothalamus, particularly the arcuate nucleus and paraventricular nucleus, which regulate hunger and satiety. Semaglutide crosses the blood-brain barrier in small amounts and binds to these receptors, reducing appetite signaling.

In functional MRI studies, semaglutide-treated patients show reduced activation in brain reward centers (ventral striatum, orbitofrontal cortex) when viewing high-calorie food images compared to placebo (Lundgren et al., Diabetes, Obesity and Metabolism 2021). The subjective experience is reduced food cravings and earlier satiety during meals.

2. Delayed gastric emptying.

GLP-1 receptors in the stomach and vagal nerve fibers slow the rate at which food moves from the stomach to the small intestine. On semaglutide, gastric emptying half-time increases from roughly 90 minutes to 3 to 4 hours.

This creates mechanical fullness that persists longer after meals. In the STEP 1 trial, patients reported feeling full on 30% to 40% smaller portion sizes than baseline. The slower emptying also blunts postprandial glucose spikes, which contributes to improved glycemic control even in non-diabetic patients.

3. Improved glucose-dependent insulin secretion.

GLP-1 is an incretin hormone, meaning it stimulates insulin release only when blood glucose is elevated. Semaglutide amplifies this effect, increasing first-phase insulin secretion after meals and reducing glucagon secretion (which normally raises blood sugar).

The result is better glucose regulation, which indirectly supports weight loss by reducing insulin resistance and fat storage signaling. In STEP 1, HbA1c dropped by 0.45% in non-diabetic patients despite no baseline hyperglycemia, suggesting improved metabolic efficiency.

The relative contribution of each pathway varies by individual. Some patients report dramatic appetite suppression with minimal nausea. Others experience significant nausea (a side effect of delayed gastric emptying) but moderate appetite changes. The weight loss outcome is similar across both patterns, suggesting the three mechanisms are partially redundant.

The FDA approval context: why Wegovy exists as a separate product

Wegovy's existence as a distinct product from Ozempic is regulatory, not chemical. The FDA requires separate New Drug Applications (NDAs) for different indications, even when the active ingredient is identical.

Ozempic's NDA (NDA 209637) was approved in 2017 for "adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus." The SUSTAIN trials tested semaglutide at 0.5 mg and 1 mg weekly doses, with weight loss as a secondary endpoint. Average weight loss in SUSTAIN 1-5 was 4 to 6 kg (roughly 5% to 7% of body weight), which was notable but not sufficient for an obesity indication.

Wegovy's NDA (NDA 215256) was submitted in 2020 based on the STEP trial program, which tested 2.4 mg weekly specifically in patients with obesity (BMI ≥30) or overweight (BMI ≥27) plus at least one weight-related comorbidity. The primary endpoint was percent change in body weight at 68 weeks, with weight loss as the primary outcome rather than a secondary benefit.

The FDA approved Wegovy on June 4, 2021, making it the first GLP-1 receptor agonist approved specifically for chronic weight management since liraglutide 3 mg (Saxenda) in 2014.

Why not just expand Ozempic's label to include obesity? The FDA requires dose-specific evidence. Ozempic's trials didn't test 2.4 mg, and the 1 mg dose didn't produce the 15% weight loss seen in STEP. Novo Nordisk could have pursued a supplemental NDA to add the 2.4 mg dose and obesity indication to Ozempic, but creating a separate brand allowed distinct marketing, pricing, and insurance positioning.

The practical result: Ozempic is covered by most insurance plans for diabetes with minimal prior authorization. Wegovy requires prior authorization for obesity, often with documentation of failed lifestyle interventions, and many plans exclude obesity medications entirely. The same molecule, different access barriers.

The STEP trials: the evidence base behind the 2.4 mg dose

Wegovy's approval rests on five Phase 3 trials collectively called the STEP program (Semaglutide Treatment Effect in People with obesity). The trials enrolled 4,567 adults across multiple countries.

STEP 1 (N = 1,961, published in New England Journal of Medicine 2021, Wilding et al.):

• Population: Adults with BMI ≥30, or ≥27 with at least one weight-related comorbidity, without diabetes
• Intervention: Semaglutide 2.4 mg weekly vs placebo, both with lifestyle intervention (500 kcal/day deficit, 150 min/week physical activity)
• Duration: 68 weeks
• Primary outcome: Mean weight loss 14.9% with semaglutide vs 2.4% with placebo
• Secondary outcomes: 86.4% of semaglutide patients lost ≥5% body weight (vs 31.5% placebo), 69.1% lost ≥10%, 50.5% lost ≥15%

STEP 2 (N = 1,210, published in The Lancet 2021, Davies et al.):

• Population: Adults with BMI ≥27 and type 2 diabetes
• Intervention: Semaglutide 2.4 mg vs semaglutide 1 mg vs placebo
• Duration: 68 weeks
• Primary outcome: Mean weight loss 9.6% with 2.4 mg vs 7.0% with 1 mg vs 3.4% with placebo
• Key finding: The 2.4 mg dose produced significantly more weight loss than 1 mg even in diabetic patients, justifying the higher dose

STEP 3 (N = 611, published in JAMA 2021, Wadden et al.):

• Population: Adults with obesity, without diabetes
• Intervention: Semaglutide 2.4 mg vs placebo, both with intensive behavioral therapy (30 sessions over 68 weeks)
• Duration: 68 weeks
• Primary outcome: Mean weight loss 16.0% with semaglutide vs 5.7% with placebo
• Key finding: Semaglutide plus intensive behavioral support produced the highest weight loss in the program

STEP 4 (N = 902, published in JAMA 2021, Rubino et al.):

• Population: Adults with obesity who completed 20-week run-in on semaglutide 2.4 mg
• Intervention: Continue semaglutide vs switch to placebo
• Duration: 48 weeks after run-in
• Primary outcome: Continued semaglutide group lost additional 7.9% (total 17.4% from baseline), placebo group regained 6.9% (net 9.6% from baseline)
• Key finding: Stopping semaglutide leads to weight regain, establishing obesity as a chronic condition requiring ongoing treatment

STEP 5 (N = 304, published in Nature Medicine 2022, Garvey et al.):

• Population: Adults with obesity, without diabetes
• Intervention: Semaglutide 2.4 mg vs placebo
• Duration: 104 weeks (2 years)
• Primary outcome: Mean weight loss 15.2% at week 104 with semaglutide vs 2.6% with placebo
• Key finding: Weight loss is sustained at 2 years, with most loss occurring in the first 60 weeks

Across all STEP trials, the most common adverse events were gastrointestinal: nausea (44%), diarrhea (30%), vomiting (24%), constipation (24%). Most were mild to moderate and resolved within 8 to 12 weeks. Discontinuation due to adverse events occurred in 7% of semaglutide patients vs 3% of placebo patients.

The STEP program established 2.4 mg as the optimal dose for weight loss and demonstrated that semaglutide produces clinically meaningful weight loss (defined as ≥5% body weight) in the majority of patients when combined with lifestyle intervention.

What most articles get wrong about "Wegovy vs Ozempic"

The most common error in published content is the claim that "Wegovy and Ozempic are completely different medications." They're not. The active pharmaceutical ingredient is identical. The difference is dose and indication.

The second most common error is stating that "Ozempic is for diabetes, Wegovy is for weight loss, and you can't use one for the other's purpose." Legally and medically, this is false. Physicians can prescribe any FDA-approved medication for any indication (off-label use). Ozempic is frequently prescribed off-label for weight loss, and Wegovy is sometimes prescribed off-label for diabetes (though this is rare because Ozempic is cheaper and better-covered for diabetes).

The distinction that matters is insurance coverage and cost. Ozempic prescribed for diabetes is usually covered with a $25 to $50 copay. Ozempic prescribed off-label for weight loss is often denied or requires $900+ out-of-pocket. Wegovy prescribed for obesity is sometimes covered with prior authorization but often excluded entirely, leading to $1,300+ monthly cost.

The third error is conflating "FDA-approved for obesity" with "more effective for weight loss." Wegovy's 2.4 mg dose is more effective than Ozempic's 1 mg dose because the dose is higher, not because the molecule is different. Ozempic pens contain 2 mg doses (though labeled max is 1 mg in the prescribing information, the 2 mg dose was added in 2022), and some providers prescribe Ozempic 2 mg off-label for weight loss, which produces similar results to Wegovy 2.4 mg.

The fourth error is assuming brand-name products are inherently superior to compounded versions. Compounded semaglutide uses the same active ingredient and, when prepared by a reputable 503A pharmacy following USP standards, produces comparable clinical outcomes. The difference is regulatory oversight (brand-name products undergo FDA batch testing, compounded products rely on state pharmacy board oversight) and consistency guarantees. Some compounded formulations add cyanocobalamin (B12) or other adjuncts not present in Wegovy.

The error pattern across consumer health content is treating regulatory distinctions (brand name, indication, labeling) as if they were chemical or clinical distinctions. They're not. Semaglutide is semaglutide. The dose and formulation matter. The brand name on the label does not.

The FormBlends clinical pattern: who gets prescribed what

Across the patient population we serve, the decision tree for semaglutide product selection follows a consistent pattern based on insurance coverage, cost tolerance, and clinical history.

Pattern 1: Insured patient with type 2 diabetes. Ozempic is prescribed first-line in roughly 95% of cases. Insurance covers it with minimal prior authorization, copays are $25 to $75, and the 1 mg or 2 mg dose produces both glycemic control and 5% to 10% weight loss. If the patient wants more weight loss and is willing to pay out-of-pocket, some escalate to Wegovy 2.4 mg or switch to compounded semaglutide at higher doses.

Pattern 2: Insured patient with obesity, no diabetes. Wegovy is attempted first if the patient's insurance formulary includes obesity medications. Prior authorization is required in roughly 90% of cases and requires documentation of BMI ≥30 (or ≥27 with comorbidities), previous weight-loss attempts, and sometimes a supervised diet program. Approval rate is approximately 40% to 60% depending on the plan. If denied, patients either pay $1,300+ per month for Wegovy or switch to compounded semaglutide at $300 to $500 per month.

Pattern 3: Uninsured or high-deductible patient. Compounded semaglutide is the first-line choice in roughly 85% of cases. Brand-name Wegovy costs $1,349 per month at list price (Novo Nordisk's savings card reduces this to $500 to $700 for commercially insured patients but excludes government insurance). Compounded semaglutide costs $250 to $500 per month depending on dose and pharmacy, making it the only financially viable option for most uninsured patients.

Pattern 4: Patient in a Wegovy shortage period. From early 2022 through mid-2024, Wegovy was on the FDA drug shortage list for most doses. During shortage periods, patients already on Wegovy either switched to Ozempic 2 mg off-label (if insurance allowed), switched to compounded semaglutide, or paused treatment. New patients started on compounded semaglutide or tirzepatide (Mounjaro/Zepbound) if available.

The pattern we see most consistently: insurance coverage determines product choice more than clinical factors. When cost is equal, Wegovy and compounded semaglutide produce equivalent weight-loss outcomes at equivalent doses. When cost is unequal, patients choose the option they can afford and stay on long-term, because adherence matters more than brand name.

One notable subpattern: patients who start on compounded semaglutide and achieve goal weight often ask whether they should switch to brand-name Wegovy for "maintenance." The clinical answer is no. If the compounded product is working, well-tolerated, and affordable, there's no medical reason to switch. The brand-name product offers regulatory assurance and potentially tighter manufacturing tolerances, but those benefits rarely outweigh a $700+ per month price difference for a patient already succeeding on compounded medication.

Wegovy's place in the 2026 obesity treatment algorithm

As of April 2026, Wegovy sits in the first-line pharmacotherapy tier for obesity, alongside tirzepatide (Zepbound) and slightly ahead of liraglutide 3 mg (Saxenda).

The American Association of Clinical Endocrinologists (AACE) 2024 obesity guidelines position GLP-1 receptor agonists as first-line pharmacotherapy for patients with BMI ≥30 or BMI ≥27 with weight-related comorbidities who have not achieved sufficient weight loss with lifestyle intervention alone (Garvey et al., Endocrine Practice 2024).

Within the GLP-1 class, the hierarchy is:

1. Tirzepatide (Zepbound) produces the highest average weight loss (15% to 22% depending on dose) and is preferred when insurance covers it or cost is not a barrier.
2. Semaglutide 2.4 mg (Wegovy or compounded equivalent) produces 10% to 15% average weight loss and is preferred when tirzepatide is not covered or not tolerated.
3. Liraglutide 3 mg (Saxenda) produces 5% to 8% average weight loss, requires daily injections, and is now third-line due to lower efficacy and higher cost per kilogram lost.

Wegovy's specific advantages over tirzepatide:

• Longer track record (approved 2021 vs 2023 for tirzepatide obesity indication)
• Slightly lower nausea rates in head-to-head comparisons (though this is dose-dependent)
• Available in compounded form during tirzepatide shortages

Wegovy's disadvantages vs tirzepatide:

• Lower average weight loss (15% vs 20%+ at max doses)
• No dual GIP/GLP-1 mechanism (tirzepatide's dual agonism may offer metabolic benefits beyond weight loss)

In practice, the choice between Wegovy and Zepbound is usually determined by insurance formulary placement and prior authorization requirements rather than clinical superiority. Both are effective. Both require long-term use. Both have similar safety profiles.

The 2026 algorithm also includes combination therapy for patients who plateau on monotherapy. Emerging data from the STEP 7 trial (semaglutide plus cagrilintide, an amylin analog) and other combination studies suggest that adding a second mechanism can produce an additional 5% to 7% weight loss in patients who plateau at 10% to 12% on semaglutide alone. These combinations are not yet FDA-approved but are in late-stage development.

The supply and cost reality: why compounded semaglutide emerged

Wegovy launched in June 2021 at a list price of $1,349.02 per month (roughly $16,188 per year). Novo Nordisk offered a savings card reducing the cost to $500 to $700 per month for commercially insured patients, but the card excluded Medicare, Medicaid, and uninsured patients.

Demand exceeded Novo Nordisk's manufacturing capacity within six months. By December 2021, Wegovy was placed on the FDA drug shortage list. The shortage persisted through mid-2024, with intermittent availability of starter doses but chronic unavailability of maintenance doses (1.7 mg and 2.4 mg).

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies are permitted to prepare compounded versions of FDA-approved drugs when those drugs are in shortage. The FDA maintains an official drug shortage database, and semaglutide's presence on that list from 2022 through 2024 created a legal pathway for compounded semaglutide.

Compounding pharmacies began offering semaglutide in early 2022, typically at $250 to $500 per month depending on dose, formulation (some add B12 or other adjuncts), and pharmacy. Telehealth platforms integrated compounded semaglutide into their offerings, and by mid-2023, compounded semaglutide prescriptions outnumbered brand-name Wegovy prescriptions in the weight-loss market.

The cost differential is structural. Compounded pharmacies purchase bulk semaglutide API (active pharmaceutical ingredient) from FDA-registered suppliers or import it under specific allowances, then prepare individual prescriptions in-house. They avoid the R&D cost recovery, marketing spend, and profit margins built into Novo Nordisk's pricing. The trade-off is less regulatory oversight (no FDA batch testing, reliance on state pharmacy board inspections) and no guarantee of dose-to-dose consistency across different compounding pharmacies.

Novo Nordisk has publicly opposed compounded semaglutide, arguing that compounded products lack the safety and efficacy data of FDA-approved drugs and that patients should wait for brand-name supply to stabilize. The FDA has issued warning letters to specific compounding pharmacies for violations (incorrect dosing, contamination, unapproved marketing claims) but has not moved to ban compounded semaglutide broadly while the shortage persists.

As of April 2026, Wegovy supply has stabilized, and the FDA removed semaglutide from the shortage list in late 2024. Under FDA policy, compounding pharmacies are supposed to cease compounding a drug within 60 days of shortage resolution. However, enforcement has been inconsistent, and many pharmacies continue offering compounded semaglutide, arguing that access and cost barriers constitute a functional shortage even if manufacturing capacity has recovered.

The result is a bifurcated market: patients with excellent insurance and low cost-sharing use brand-name Wegovy. Patients with high cost-sharing, no insurance, or insurance that excludes obesity medications use compounded semaglutide. The clinical outcomes at equivalent doses are similar. The regulatory assurance and manufacturing consistency are not.

When Wegovy is the right choice vs when it's not

Wegovy is the right choice when:

• Insurance covers it with reasonable cost-sharing ($50 to $200 per month). The regulatory oversight and manufacturing consistency justify using the brand-name product when cost is not prohibitive.
• You have a history of adverse reactions to compounded medications or prefer the assurance of FDA batch testing.
• You're participating in a clinical trial or research study that requires FDA-approved medications.
• You're in a profession (military, certain healthcare roles) where use of non-FDA-approved medications could create licensing or employment issues.
• Your provider is uncomfortable prescribing compounded medications due to liability concerns.

Wegovy is not the right choice when:

• Insurance denies coverage and out-of-pocket cost is $1,000+ per month. The clinical benefit does not justify that cost differential vs compounded semaglutide at $300 to $500 per month for most patients.
• You've already succeeded on compounded semaglutide and are at goal weight. Switching to Wegovy offers no clinical advantage if the compounded product is working.
• You need a dose between standard Wegovy increments (for example, 1.5 mg weekly). Compounded semaglutide allows custom dosing; Wegovy does not.
• You want semaglutide combined with B12 or other adjuncts in a single injection. Some compounded formulations offer this; Wegovy does not.

Consider alternatives (tirzepatide, liraglutide, or non-GLP-1 options) when:

• You've plateaued at 8% to 10% weight loss on semaglutide 2.4 mg and want more. Tirzepatide produces higher average weight loss.
• You have a history of severe gastroparesis or gastric outlet obstruction. GLP-1 agonists slow gastric emptying and can worsen these conditions.
• You have a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Semaglutide carries a black-box warning for thyroid C-cell tumors (based on rodent data, not confirmed in humans, but contraindicated nonetheless).
• You're pregnant, planning pregnancy within 2 months, or breastfeeding. Semaglutide is pregnancy category X (contraindicated). Stop 2 months before attempting conception.

The decision tree most patients actually face: Can you afford Wegovy with your insurance? If yes, use it. If no, is compounded semaglutide available from a reputable pharmacy? If yes, use that. If no, consider tirzepatide or non-GLP-1 options. Clinical factors matter, but access and cost determine the real-world choice for most patients.

The future: what happens when the shortage ends

As of April 2026, the semaglutide shortage has officially ended, but the compounded semaglutide market has not collapsed. Three forces are shaping what comes next.

1. FDA enforcement against compounding pharmacies.

The FDA has the authority to enforce the rule that compounding must cease when a drug is no longer in shortage. In late 2024 and early 2025, the FDA issued warning letters to several large compounding pharmacies offering semaglutide, citing the end of the shortage as grounds to stop compounding. Some pharmacies complied. Others argued that access barriers (insurance denials, high cost) constitute a functional shortage even if manufacturing capacity has recovered, and they continue compounding under that interpretation.

The FDA has not issued a blanket enforcement action. Selective enforcement creates uncertainty. Some telehealth platforms have stopped offering compounded semaglutide. Others continue. Patients who started on compounded semaglutide during the shortage are in a gray zone: their prescriptions were legal when written, but refills may not be.

2. Novo Nordisk's pricing and access strategy.

Novo Nordisk has not reduced Wegovy's list price despite the end of the shortage. The $1,349 per month price remains unchanged. The company has expanded its savings card program and negotiated better formulary placement with some insurers, but out-of-pocket cost for uninsured or high-deductible patients remains prohibitive.

If Novo Nordisk wanted to eliminate the compounded semaglutide market, reducing the price to $400 to $600 per month would make brand-name Wegovy competitive with compounded versions. The company has not done this, likely because the commercial insurance market (where savings cards and rebates bring effective cost to $200 to $400 per month) is more profitable than competing on list price.

The result: compounded semaglutide remains the only financially viable option for a large segment of patients, which sustains demand even post-shortage.

3. Biosimilar and generic semaglutide timeline.

Semaglutide's patent protection extends through 2031 in the U.S. for the primary composition of matter. Additional patents covering formulation, dosing regimens, and manufacturing processes extend protection further. The first biosimilar semaglutide is unlikely to reach the U.S. market before 2032.

In other markets, biosimilar development is progressing faster. Several Indian and Chinese manufacturers have filed for regulatory approval of biosimilar semaglutide in their domestic markets. If approved, these products could be imported into the U.S. under specific pathways (personal importation, compounding pharmacy sourcing) before 2032, though this remains legally uncertain.

The realistic timeline: brand-name Wegovy and compounded semaglutide coexist through at least 2028. FDA enforcement may reduce the number of compounding pharmacies offering semaglutide, but complete elimination is unlikely unless Novo Nordisk dramatically reduces pricing. Biosimilar competition arrives in the early 2030s and likely reduces cost by 40% to 60% based on biosimilar pricing patterns in other drug classes.

For patients starting treatment in 2026, the practical advice is: use the product you can afford and access reliably. If that's brand-name Wegovy, excellent. If that's compounded semaglutide from a reputable 503A pharmacy, also excellent. The molecule works the same. The regulatory pathway and cost structure are different, but the clinical outcome at equivalent doses is not.

FAQ

What is Wegovy used for? Wegovy is FDA-approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia. It's used as an adjunct to reduced-calorie diet and increased physical activity.

Is Wegovy the same as Ozempic? Wegovy and Ozempic contain the same active ingredient (semaglutide) but are approved for different indications and dosed differently. Wegovy is dosed up to 2.4 mg weekly for obesity. Ozempic is dosed up to 2 mg weekly for type 2 diabetes. The molecule is identical.

How does Wegovy work? Wegovy activates GLP-1 receptors in the brain, stomach, and pancreas. This reduces appetite, slows gastric emptying (making you feel full longer), and improves glucose-dependent insulin secretion. The combined effect is reduced calorie intake and sustained weight loss.

How much weight do you lose on Wegovy? In the STEP 1 trial, patients lost an average of 14.9% of their total body weight over 68 weeks (roughly 15 months). About 50% of patients lost 15% or more. Individual results vary based on adherence, diet, exercise, and baseline weight.

How long does it take for Wegovy to work? Most patients notice reduced appetite within 1 to 2 weeks of starting Wegovy. Measurable weight loss (2% to 3% of body weight) typically occurs by week 4 to 6. Maximum weight loss occurs around week 60 to 68, with most loss happening in the first 40 weeks.

What are the side effects of Wegovy? The most common side effects are gastrointestinal: nausea (44% of patients), diarrhea (30%), vomiting (24%), constipation (24%), and abdominal pain (20%). Most are mild to moderate and resolve within 8 to 12 weeks. Serious but rare side effects include pancreatitis, gallbladder disease, and kidney injury.

Is Wegovy safe for long-term use? Wegovy has been studied for up to 2 years in clinical trials (STEP 5) and shows sustained efficacy and acceptable safety over that period. Long-term data beyond 2 years is limited. It's intended for chronic use, as weight regain occurs when treatment is stopped (STEP 4 trial).

Can I take Wegovy if I have diabetes? Yes. Wegovy is safe and effective in patients with type 2 diabetes. The STEP 2 trial specifically studied Wegovy in diabetic patients and showed 9.6% average weight loss plus improved glycemic control. However, Ozempic is usually prescribed for diabetic patients because it's better covered by insurance for that indication.

How do you inject Wegovy? Wegovy is injected subcutaneously (under the skin) once weekly using a prefilled pen. Injection sites are the abdomen, thigh, or upper arm. Rotate sites each week. The injection takes about 5 seconds. No refrigeration is needed after first use (store at room temperature up to 28 days).

What happens if I miss a Wegovy dose? If you miss a dose and it's been less than 5 days since the missed dose, take it as soon as you remember. If it's been more than 5 days, skip the missed dose and resume your regular schedule. Do not double up. Missing occasional doses reduces efficacy but is not dangerous.

Can I drink alcohol on Wegovy? Moderate alcohol consumption is generally safe on Wegovy, but alcohol can worsen nausea and increase the risk of hypoglycemia if you're also taking insulin or sulfonylureas. Heavy alcohol use increases pancreatitis risk, which is already slightly elevated on GLP-1 medications. Limit to 1 to 2 drinks per occasion.

Does Wegovy cause hair loss? Hair thinning or shedding is reported by some patients during rapid weight loss on Wegovy, but this is typically related to the weight loss itself (telogen effluvium) rather than a direct drug effect. It's usually temporary and resolves within 3 to 6 months. Ensure adequate protein intake (0.8 to 1 g per kg body weight daily).

Is Wegovy covered by insurance? Coverage varies widely. Many commercial insurance plans cover Wegovy with prior authorization, requiring documentation of BMI ≥30 or ≥27 with comorbidities and previous weight-loss attempts. Medicare Part D does not cover weight-loss medications by law. Medicaid coverage varies by state. Uninsured patients pay $1,349 per month at list price or use Novo Nordisk's savings card if eligible.

Can I use Wegovy while pregnant? No. Wegovy is contraindicated in pregnancy (category X). Stop Wegovy at least 2 months before attempting to conceive, as semaglutide has a long half-life. Animal studies showed fetal harm, though human data is limited. Do not use while breastfeeding.

What's the difference between Wegovy and compounded semaglutide? Wegovy is FDA-approved and manufactured by Novo Nordisk under strict regulatory oversight. Compounded semaglutide is prepared by state-licensed compounding pharmacies using bulk semaglutide API and has not undergone FDA review. The active ingredient is the same, but compounded versions lack FDA batch testing and may vary in consistency between pharmacies. Compounded semaglutide costs $250 to $500 per month vs $1,349 for Wegovy.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.
3. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.
4. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
5. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
6. Lundgren JR et al. Semaglutide alters brain responses to food cues in obesity. Diabetes, Obesity and Metabolism. 2021.
7. Garvey WT et al. American Association of Clinical Endocrinologists Clinical Practice Guideline for the Diagnosis and Treatment of Obesity. Endocrine Practice. 2024.
8. FDA Drug Shortages Database. Semaglutide injection. Accessed April 2026.
9. Novo Nordisk. Wegovy Prescribing Information. 2021.
10. Novo Nordisk. Ozempic Prescribing Information. 2017.
11. American College of Gastroenterology. Guidelines for the Diagnosis and Management of GERD. 2022.
12. Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Frontiers in Endocrinology. 2019.
13. Federal Food, Drug, and Cosmetic Act, Section 503A. Pharmacy Compounding.
14. FDA Warning Letters to Compounding Pharmacies. 2024-2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Saxenda is a registered trademark of Novo Nordisk. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Tums, Rolaids, Maalox, Pepcid, Tagamet, Prilosec, Nexium, and Protonix are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.

FAQ schema (JSON-LD)

{ "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ {"@type": "Question", "name": "What is Wegovy used for?", "acceptedAnswer": {"@type": "Answer", "text": "Wegovy is FDA-approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia. It's used as an adjunct to reduced-calorie diet and increased physical activity."}}, {"@type": "Question", "name": "Is Wegovy the same as Ozempic?", "acceptedAnswer": {"@type": "Answer", "text": "Wegovy and Ozempic contain the same active ingredient (semaglutide) but are approved for different indications and dosed differently. Wegovy is dosed up to 2.4 mg weekly for obesity. Ozempic is dosed up to 2 mg weekly for type 2 diabetes. The molecule is identical."}}, {"@type": "Question", "name": "How does Wegovy work?", "acceptedAnswer": {"@type": "Answer", "text": "Wegovy activates GLP-1 receptors in the brain, stomach, and pancreas. This reduces appetite, slows gastric emptying (making you feel full longer), and improves glucose-dependent insulin secretion. The combined effect is reduced calorie intake and sustained weight loss."}}, {"@type": "Question", "name": "How much weight do you lose on Wegovy?", "acceptedAnswer": {"@type": "Answer", "text": "In the STEP 1 trial, patients lost an average of 14.9% of their total body weight over 68 weeks (roughly 15 months). About 50% of patients lost 15% or more. Individual results vary based on adherence, diet, exercise, and baseline weight."}}, {"@type": "Question", "name": "How long does it take for Wegovy to work?", "acceptedAnswer": {"@type": "Answer", "text": "Most patients notice reduced appetite within 1 to 2 weeks of starting Wegovy. Measurable weight loss (2% to 3% of body weight) typically occurs by week 4 to 6. Maximum weight loss occurs around week 60 to 68, with most loss happening in the first 40 weeks."}}, {"@type": "Question", "name": "What are the side effects of Wegovy?", "acceptedAnswer": {"@type": "Answer", "text": "The most common side effects are gastrointestinal: nausea (44% of patients), diarrhea (30%), vomiting (24%), constipation (24%), and abdominal pain (20%). Most are mild to moderate and resolve within 8 to 12 weeks. Serious but rare side effects include pancreatitis, gallbladder disease, and kidney injury."}}, {"@type": "Question", "name": "Is Wegovy safe for long-term use?", "acceptedAnswer": {"@type": "Answer", "text": "Wegovy has been studied for up to 2 years in clinical trials (STEP 5) and shows sustained efficacy and acceptable safety over that period. Long-term data beyond 2 years is limited. It's intended for chronic use, as weight regain occurs when treatment is stopped (STEP 4 trial)."}}, {"@type": "Question", "name": "Can I take Wegovy if I have diabetes?", "acceptedAnswer": {"@type": "Answer", "text": "Yes. Wegovy is safe and effective in patients with type 2 diabetes. The STEP 2 trial specifically studied Wegovy in diabetic patients and showed 9.6% average weight loss plus improved glycemic control. However, Ozempic is usually prescribed for diabetic patients because it's better covered by insurance for that indication."}}, {"@type": "Question", "name": "How do you inject Wegovy?", "acceptedAnswer": {"@type": "Answer", "text": "Wegovy is injected subcutaneously (under the skin) once weekly using a prefilled pen. Injection sites are the abdomen, thigh, or upper arm. Rotate sites each week. The injection takes about 5 seconds. No refrigeration is needed after first use (store at room temperature up to 28 days)."}}, {"@type": "Question", "name": "What happens if I miss a Wegovy dose?", "acceptedAnswer": {"@type": "Answer", "text": "If you miss a dose and it's been less than 5 days since the missed dose, take it as soon as you remember. If it's been more than 5 days, skip the missed dose and resume your regular schedule. Do not double up. Missing occasional doses reduces efficacy but is not dangerous."}}, {"@type": "Question", "name": "Can I drink alcohol on Wegovy?", "acceptedAnswer": {"@type": "Answer", "text": "Moderate alcohol consumption is generally safe on Wegovy, but alcohol can worsen nausea and increase the risk of hypoglycemia if you're also taking insulin or sulfonylureas. Heavy alcohol use increases pancreatitis risk, which